Prof. Giuseppe Curigliano, European Institute of Oncology, Italy
Prof. Zhonghua Tao, Fudan University Shanghai Cancer Center, China
Prof. Curigliano and Prof. Tao discussed how to balance the use of T-DXd in the neoadjuvant versus adjuvant settings for HER2-positive early breast cancer, in light of emerging evidence from the DB-05 and DB-11 studies. They explored which patient characteristics and biomarkers may help guide clinical decision-making, and also shared perspectives on potential differences between Chinese and international patients.